Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis B Cortot

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Clinical Lung Cancer|April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for ManagementRemi Veillon, Hiroshi Sakai, Xiuning Le, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 TrialJulien Mazieres, Claire Lafitte, Charles Ricordel, et al.
Lung Cancer (Amsterdam, Netherlands)|October 15, 2023
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)Agathe Dehem, Julien Mazieres, Ali Chour, et al.
Oncoimmunology|April 22, 2020
Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance databaseQuentin Scanvion, Johana Béné, Sophie Gautier, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutationJean Bernard Auliac, Maurice Pérol, David Planchard, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm studySimon Baldacci, Martin Figeac, Martine Antoine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.
Therapeutic Advances in Medical Oncology|June 13, 2022
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric studyGeoffroy Bilger, Anne-Claire Toffart, Marie Darrason, et al.
Cancer Medicine|January 25, 2025
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT StudyGeoffrey Liu, Shi Feng Nyaw, Tony S K Mok, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Clinical Lung Cancer|April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for ManagementRemi Veillon, Hiroshi Sakai, Xiuning Le, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 TrialJulien Mazieres, Claire Lafitte, Charles Ricordel, et al.
Lung Cancer (Amsterdam, Netherlands)|October 15, 2023
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)Agathe Dehem, Julien Mazieres, Ali Chour, et al.
Oncoimmunology|April 22, 2020
Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance databaseQuentin Scanvion, Johana Béné, Sophie Gautier, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutationJean Bernard Auliac, Maurice Pérol, David Planchard, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm studySimon Baldacci, Martin Figeac, Martine Antoine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.
Therapeutic Advances in Medical Oncology|June 13, 2022
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric studyGeoffroy Bilger, Anne-Claire Toffart, Marie Darrason, et al.
Cancer Medicine|January 25, 2025
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT StudyGeoffrey Liu, Shi Feng Nyaw, Tony S K Mok, et al.
Pageof 8